These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19848596)

  • 1. Cancer gene therapy: present and future.
    Bonini C; Gansbacher B
    Hum Gene Ther; 2009 Oct; 20(10):1100. PubMed ID: 19848596
    [No Abstract]   [Full Text] [Related]  

  • 2. T-cell receptor gene therapy: critical parameters for clinical success.
    Linnemann C; Schumacher TN; Bendle GM
    J Invest Dermatol; 2011 Sep; 131(9):1806-16. PubMed ID: 21677669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell receptor gene therapy for cancer: the progress to date and future objectives.
    Thomas S; Hart DP; Xue SA; Cesco-Gaspere M; Stauss HJ
    Expert Opin Biol Ther; 2007 Aug; 7(8):1207-18. PubMed ID: 17696819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding suitable targets is the major obstacle to cancer gene therapy.
    Rosenberg SA
    Cancer Gene Ther; 2014 Feb; 21(2):45-7. PubMed ID: 24535159
    [No Abstract]   [Full Text] [Related]  

  • 5. Atelocollagen-mediated siRNA delivery: future promise for therapeutic application.
    Fujimoto I; Takei Y
    Ther Deliv; 2014 Apr; 5(4):369-71. PubMed ID: 24856162
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer gene therapy: present status and future directions.
    Nabel GJ
    Ernst Schering Res Found Workshop; 2003; (43):81-8. PubMed ID: 12894452
    [No Abstract]   [Full Text] [Related]  

  • 7. [Adoptive immunotherapy for cancer with genetically engineered T cells].
    Ikeda H; Okamoto S; Mineno J; Imai N; Ito M; Yasukawa M; Takesako K; Shiku H
    Rinsho Ketsueki; 2010 Nov; 51(11):1647-53. PubMed ID: 21157127
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic re-targeting of T lymphocyte specificity.
    Bolhuis RL; Gratama JW
    Gene Ther; 1998 Sep; 5(9):1153-5. PubMed ID: 9930314
    [No Abstract]   [Full Text] [Related]  

  • 9. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.
    Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C
    Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling.
    Ribas A; Koya RC
    Future Oncol; 2010 Nov; 6(11):1671-3. PubMed ID: 21142653
    [No Abstract]   [Full Text] [Related]  

  • 11. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status and future prospects of gene therapy].
    Ozawa K
    Nihon Ronen Igakkai Zasshi; 1999 Oct; 36(10):690-4. PubMed ID: 10614121
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer gene therapy annual conference 1997: trends and news.
    Paillard F
    Hum Gene Ther; 1998 Feb; 9(3):283-6. PubMed ID: 9508045
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhanced T cell receptor gene therapy for cancer.
    Kieback E; Uckert W
    Expert Opin Biol Ther; 2010 May; 10(5):749-62. PubMed ID: 20201709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell engineering for cancer immunotherapy.
    Sadelain M
    Cancer J; 2009; 15(6):451-5. PubMed ID: 20010162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy: into the future of surgery.
    Hollingsworth SJ; Barker SG
    Lancet; 1999 Apr; 353 Suppl 1():SI19-20. PubMed ID: 10319927
    [No Abstract]   [Full Text] [Related]  

  • 17. TCR repertoires of intratumoral T-cell subsets.
    Linnemann C; Mezzadra R; Schumacher TN
    Immunol Rev; 2014 Jan; 257(1):72-82. PubMed ID: 24329790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gendicine: the first commercial gene therapy product.
    Wilson JM
    Hum Gene Ther; 2005 Sep; 16(9):1014-5. PubMed ID: 16149899
    [No Abstract]   [Full Text] [Related]  

  • 19. Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.
    Chicaybam L; Bonamino MH
    Int Rev Immunol; 2014 Oct; 33(5):402-16. PubMed ID: 24911925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive T-cell therapy for cancer: The era of engineered T cells.
    Bonini C; Mondino A
    Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.